Huntington Disease
📧 Sign up to get email alerts when something new happens for Huntington Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects [Phase 1]
Phase 1 study assessing safety, tolerability and pharmacokinetics of escalating doses of LPM3770164 in healthy subjects, with potential rele…
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets [Phase 1]
A Phase 1 clinical trial evaluating the effect of food on the pharmacokinetics of LPM3770164 sustained-release tablets. The study is complet…
-
CLINICAL_TRIALS research · 2024-12-06Clinical Trial Update: Extracellular Vesicles for HD
A University of Central Florida-sponsored study is recruiting participants to evaluate extracellular vesicles as a potential therapy for Hun…
-
FDA label_change · 2024-11-26FDA Approved: AUSTEDO — Supplemental Application (Teva Neuroscience, Inc.)
FDA approved a supplemental application for AUSTEDO (deutetrabenazine) from Teva Neuroscience, Inc., updating the product labeling.
-
CLINICAL_TRIALS research · 2024-11-18Clinical Trial Update: Huntington's Disease and Pain
A clinical trial update from Leiden University Medical Center concerns Huntington's disease with pain. The study status is NOT_YET_RECRUITIN…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-11-12Clinical Trial Update: Clinical Study to Monitor Plasma Levels of 24OHC in Subject with HD
The clinical study monitoring plasma levels of 24-hydroxycholesterol in a subject with Huntington's disease has completed.
-
CLINICAL_TRIALS trial_result · 2024-11-04Clinical Trial Update: A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease [Phase 2]
A Phase 2 dose-ranging study with an open-label extension evaluated the safety of oral branaplam (LMI070) in individuals with early manifest…
-
CLINICAL_TRIALS trial_result · 2024-10-03Clinical Trial Update: A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease [Phase 1]
Phase 1 study evaluating pharmacokinetics, pharmacodynamics, and safety/tolerability of intrathecal RO7234292 (RG6042) in Huntington's disea…
-
CLINICAL_TRIALS research · 2024-09-03Clinical Trial Update: Prospective Huntington At Risk Observational Study
The Prospective Huntington At Risk Observational Study sponsored by the Huntington Study Group has completed.
-
CLINICAL_TRIALS research · 2024-08-02Clinical Trial Update: Biological Sample Collection for Research and Biobanking
Termination notice for a New York Stem Cell Foundation Research Institute–led study collecting biological samples for research and biobankin…
-
CLINICAL_TRIALS trial_result · 2024-07-15Clinical Trial Update: A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease [Phase 2]
This completed Phase 2 trial evaluated Triheptanoin as anaplerotic therapy for Huntington disease.
-
FDA approval · 2024-07-01FDA Approved: AUSTEDO XR — Supplemental Application (Teva Neuroscience, Inc.)
The FDA approved Teva's supplemental application for AUSTEDO XR (deutetrabenazine), an extended-release formulation of Austedo.
-
FDA approval · 2024-05-29FDA Approved: AUSTEDO XR — Supplemental Application (Teva Neuroscience, Inc.)
FDA approved a supplemental application for AUSTEDO XR (deutetrabenazine) by Teva Neuroscience, expanding the product to include an extended…
-
CLINICAL_TRIALS research · 2024-05-07Clinical Trial Update: Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression [NA]
A clinical trial investigating innovative imaging and cognitive biomarkers to predict Huntington's disease progression is currently recruiti…
-
CLINICAL_TRIALS research · 2024-04-30Clinical Trial Update: Huntington's Disease Young Adult Study 2.0
This document provides an update on a Huntington's disease clinical trial called 'Young Adult Study 2.0' conducted by University College Lon…
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease [Phase 3]
Phase 3 study evaluating dextromethorphan/quinidine for irritability in Huntington's disease has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease [Phase 3]
Phase 3 trial evaluating intrathecal RO7234292 (RG6042) for Huntington's disease has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-10-24Clinical Trial Update: Efficacy and Safety of NestaCell® in Huntington's Disease [Phase 3]
Phase 3 trial update on NestaCell® for Huntington's disease, focusing on efficacy and safety.
-
CLINICAL_TRIALS trial_result · 2023-10-11Clinical Trial Update: Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease [Phase 3]
Phase 3 trial update on valbenazine for chorea in Huntington disease, reporting efficacy, safety, and tolerability results.
-
FDA approval · 2023-09-28FDA Approved: AUSTEDO — Supplemental Application (Teva Neuroscience, Inc.)
FDA approved a supplemental application for Austedo (deutetrabenazine) submitted by Teva Neuroscience, Inc. The approval updates the labelin…
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease [Phase 2]
Phase 2 trial update on fenofibrate for Huntington's disease, reporting safety and efficacy results.
-
CLINICAL_TRIALS trial_result · 2023-08-31Clinical Trial Update: An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies [Phase 3]
Open-label extension study assessing long-term safety and tolerability of RO7234292 (RG6042) in Huntington's disease participants from prior…
-
CLINICAL_TRIALS trial_result · 2023-08-31Clinical Trial Update: A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease [Phase 2]
A Phase 2 clinical trial of pridopidine (ACR16) for Huntington's disease has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-08-29Clinical Trial Update: A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease [Phase 3]
Phase 3 clinical trial update for pridopidine (ACR16) in Huntington's Disease has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease [Phase 2]
Phase 2 trial update on SRX246 assessing tolerability, safety, and activity in irritable mood associated with Huntington's disease; study co…